Fig. 6
ProgModule can be used to predict the clinical outcomes of patients receiving immunotherapy. (A) The enriched KEGG pathways of genes involved in all candidate modules in the Van Allen cohort. (B) Circle plot depicting the impact on melanoma overall survival of five candidate module mutations. (C) Kaplan-Meier survival analysis of OS comparing the High-risk and Low-risk groups from the Van Allen cohort. (D) Comparison of ORR between the High-risk and Low-risk groups in the Van Allen cohort. (E) Kaplan-Meier survival analysis of OS comparing the High-risk and Low-risk groups from the Miao cohort. (F) Comparison of ORR between the High-risk and Low-risk groups in the Miao cohort. (G) Compared the performance of our method with other published immunotherapy biomarkers based on C-index and MCC. (H) Heatmap depicting the Z score of seven candidate genes in the top 10% of ranked genes across different CRISPR datasets